PDUFA Dates in November 2026: 4 FDA Decisions to Watch
4 FDA PDUFA target dates in November 2026: CAPR Nov 22, BBIO Nov 27, COGT Nov 30, VRTX Nov 30. Every date is sourced to a company SEC filing and verified.
FDA decisions expected in November 2026
This is every PDUFA target action date in November 2026 that a company has stated in an SEC filing and that BiotechSign has verified. A PDUFA date is the FDA's goal date for acting on an application. It is a target, not a promise: the agency can act earlier, on the day, or later, and a major amendment to an application can extend the goal date by three months.
- Nov 22, 2026 · CAPR (Capricor Therapeutics, Inc.): Deramiocel — Duchenne muscular dystrophy (DMD). Source: the company's own SEC filing, dated Aug 24, 2026.
- Nov 27, 2026 · BBIO (BridgeBio Pharma): BBP-418. Source: the company's own SEC filing, dated May 27, 2026.
- Nov 30, 2026 · COGT (Cogent Biosciences): FDA decision on the program named in the filing. Source: the company's own SEC filing, dated Nov 5, 2026.
- Nov 30, 2026 · VRTX (Vertex Pharmaceuticals): povetacicept — IgAN. Source: the company's own SEC filing, dated Aug 3, 2026.
Last updated November 14, 2026. This list is generated from BiotechSign's verified data and refreshes automatically when a date is added, changed, or removed. See the full, filterable PDUFA calendar for every upcoming date.
How to read a PDUFA date
The FDA does not publish PDUFA dates itself. Companies disclose them in press releases and SEC filings, which is why each date above links to the filing it came from. When a company announces a new date, for example after the FDA extends its review, the calendar and this page update to match.
The FDA's decision is usually an approval or a complete response letter. A complete response letter means the application cannot be approved in its current form, and it often moves the stock sharply. Our PDUFA dates guide explains the review timeline, and the PDUFA trading strategies guide covers how investors approach these events.
Companies often raise capital around catalysts, so check the financing picture as well as the date. The dilution risk guide explains what to look for, and each company page shows BiotechSign's catalyst grade and risk notes.
BiotechSign provides data for informational purposes only. This is not financial advice.